4/A: Aquestive Therapeutics Executive Stephen Wargacki Reports Stock Disposal for Tax Obligations
SEC Form 4/A
Stephen Wargacki, Chief Science Officer of Aquestive Therapeutics, reports disposing of shares to cover tax obligations related to vesting Restricted Stock Units.
Summary
- On March 9, 2024, Stephen Wargacki, Chief Science Officer of Aquestive Therapeutics, Inc., disposed of 19,505 shares of common stock to satisfy tax withholding obligations.
- The shares were withheld by the issuer at a price of $4.88 per share.
- Following the transaction, Wargacki beneficially owns 261,414 shares of Aquestive Therapeutics.
- This Form 4/A amends a previous filing on March 12, 2024, to revise the number of shares withheld for tax obligations.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing relates to a routine tax obligation and does not indicate a change in the executive's confidence in the company.
Industry Context
Executive stock transactions are common and often related to compensation and tax planning. The disposal of shares to cover tax obligations is a routine event.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/09/2024 | Date of stock disposal transaction. |
| 03/12/2024 | Date of original Form 4 filing. |
| 10/02/2024 | Date of signature on the amended Form 4/A. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.